,11, 12, 13, 14 Despite conflicting evidence of ErbB4 in oncogenesis, ErbB4 mutations have been reported in melanoma (19%) and overexpressed in colorectal cancer.14, 15, 16, 17 The prevalence of these alterations have led to the development ErbB inhibitors as antineoplastic therapies. The gene discussed is ERBB4; the disease is melanoma.